Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accounts Payables (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accounts Payables data on record, last reported at $1.6 million in Q1 2026.

  • On a quarterly basis, Accounts Payables fell 6.19% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 million, a 6.19% decrease, with the full-year FY2025 number at $1.2 million, up 22.8% from a year prior.
  • Accounts Payables reached $1.6 million in Q1 2026 per IKT's latest filing, up from $1.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for IKT hit a ceiling of $19.0 million in Q2 2023 and a floor of $620528.0 in Q3 2025.
  • A 5-year average of $2.5 million and a median of $1.2 million in 2025 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 2111.64% in 2023, then tumbled 82.26% in 2024.
  • Tracing IKT's Accounts Payables over 5 years: stood at $1.2 million in 2022, then tumbled by 43.82% to $646767.0 in 2023, then surged by 45.81% to $943019.0 in 2024, then increased by 22.8% to $1.2 million in 2025, then soared by 37.07% to $1.6 million in 2026.
  • Business Quant data shows Accounts Payables for IKT at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $620528.0 in Q3 2025.